GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (OTCPK:WUXIF) » Definitions » Loans Receivable

WUXIF (Wuxi AppTec Co) Loans Receivable : $0 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Wuxi AppTec Co Loans Receivable?

Wuxi AppTec Co's Loans Receivable for the quarter that ended in Dec. 2024 was $0 Mil.


Wuxi AppTec Co Loans Receivable Historical Data

The historical data trend for Wuxi AppTec Co's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co Loans Receivable Chart

Wuxi AppTec Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Wuxi AppTec Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Wuxi AppTec Co Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Wuxi AppTec Co Loans Receivable Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuxi AppTec Co Business Description

Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, gene therapies, and testing services for medical devices. Its segments comprise WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It generates the majority of its revenue from the WuXi Chemistry segment. Its geographic areas are the PRC, USA, Europe, and the Rest of the world, in which it generates the majority of its revenue from the USA.